NODAS

NODAS operates at the intersection of neurotechnology, medical devices, diagnostics, and retinal imaging. Its stated differentiation is a portable, non-mydriatic hyperspectral fundus camera paired with AI analysis and longitudinal data, rather than imaging hardware alone. The HVC-1201 is described as capturing 16 channels across 450–620 nm in under 0.2 seconds, while automated eye tracking and focusing are intended to support image capture. The broader product concept uses repeated measurements to map disease dynamics and pursue earlier screening for Alzheimer’s disease. Conventional retinal imaging and other diagnostic approaches provide relevant context, but there is not enough evidence to claim superiority over them. NODAS’s most identifiable positioning is its combination of hyperspectral retinal capture, portability, and a longitudinal-data platform, with academic and medical collaborations described in Japan and China but not named.

NODAS was founded on Dec 1, 2023 and is listed as active, giving it a relatively short operating history as of Oct 7, 2026. Its described development focus is a portable hyperspectral retinal imaging system for early Alzheimer’s disease screening. The HVC-1201’s stated specifications—16 spectral channels, capture in under 0.2 seconds, no pupil dilation, and a weight below 3 kg—indicate a defined hardware concept, while AI analysis and longitudinal data are intended to extend the product toward disease-progression mapping. NODAS mentions collaborations with academic and medical institutions in Japan and China, but provides no names, dates, or specific outcomes here. Its growth trajectory therefore remains difficult to quantify.